SCHEMBL3300262

SCHEMBL3300262

Cc1cccc(CNc2nc3c(c(=O)n2-c2ccccc2)CN(C(=O)Nc2ccc(F)c(F)c2)CC3)c1

nearest known ligand 0.44

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CLPP Q16740 2/20 0.40
PRLHR P49683 2/20 0.39
FAAH O00519 1/20 0.39
KDR P35968 1/20 0.39
NAMPT P43490 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3296928 0.93 CLPP (0.43) CLPPPRLHRNAMPT
SCHEMBL3302814 0.92 PRLHR (0.43) CLPPPRLHRNAMPT
SCHEMBL3297401 0.92 CLPP (0.41) CLPPPRLHRFAAHNAMPT
SCHEMBL3294275 0.92 CLPP (0.39) CLPP
SCHEMBL3295357 0.92 CACNA1H (0.43) CLPPPRLHRFAAH
SCHEMBL3303714 0.91 CLPP (0.40) CLPPPRLHR
SCHEMBL3298232 0.91 NAMPT (0.40) CLPPPRLHRNAMPT
SCHEMBL3297983 0.91 NPC1 (0.42) PRLHRFAAHNAMPT
SCHEMBL3297276 0.90 MAPK1 (0.38)
SCHEMBL3295196 0.89 PRLHR (0.43) CLPPPRLHRFAAHNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232282-B2 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-31 US disclosed
US-20100093771-A1 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-04-15 US disclosed
EP-2078719-A1 COMPOUND HAVING BICYCLIC PYRIMIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2009-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093771-A1 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same GART, MGAT2, MGAT1 CLPP 4670/4885PRLHR 3093/4885FAAH 1397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.